Sussex Partner Formulary
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
    • 2025
    • 2024
    • 2023
  • APC Minutes
  • Discontinuations
  • Contact us
  • About The Formulary
  • Using The Formulary
  • Therapeutic Sections
    • 1 Gastro-intestinal system
    • 2 Cardiovascular system
      • 2.1 Arrhythmias
      • 2.2 Bleeding disorders
      • 2.3 Blood clots
      • 2.4 Blood pressure conditions
      • 2.5 Cardiovascular risk assessment and prevention
      • 2.6 Heart failure
      • 2.7 Hyperlipidaemia
      • 2.8 Myocardial ischaemia
        • 2.8.1 Acute coronary syndromes
        • 2.8.1a Cardiac arrest
      • 2.9 Vascular disease
      • 2.10 Other Cardiovascular system items
    • 3 Respiratory system
    • 4 Nervous system
    • 5 Infection
    • 6 Endocrine system
    • 7 Genito-urinary system
    • 8 Immune system & malignant disease
    • 9 Blood and nutrition
    • 10 Musculoskeletal system
    • 11 Eye
    • 12 Ear, nose and oropharynx
    • 13 Skin
    • 14 Vaccines
    • 15 Anaesthesia
    • 16 Emergency treatment of poisoning
    • 17 Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum
    • Appendix 1 - Borderline substances
    • Appendix 2 - Wound management products and elasticated garments
    • Appendix 3 - Continence
    • Appendix 4 - Palliative care
  • Drug Index
  • Antimicrobial Guidance
  • Shared Care Protocols
  • Position statements
  • Not Recommended Items
  • APC Summaries
  • APC Minutes
  • Discontinuations
  • Contact us
  • Search

Drug Status Key

  • Non-Specialist Drugs
  • Specialist recommendation (or initiation where noted)
  • Specialist Initiation WITH Shared Care Guidelines
  • Specialist ONLY Drugs
  • Mixed Status - See individual drug entries for more details

Preferences

  • First Line
  • Second Line
  • Third Line
  • No Preference

Eptifibatide

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Eptifibatide 20mg/10ml solution for injection vials

Pack
1 vial

Eptifibatide 75mg/100ml solution for infusion vials

Pack
1 vial

Ivabradine

{ Value = MHRA Warning Exists, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Must be initiated by a heart failure specialist.

Ivabradine 5mg tablets

Pack
56 tablet

Ivabradine 7.5mg tablets

Pack
56 tablet

Nicorandil

{ Value = MHRA Warning Exists, Index = 4 } { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Nicorandil 10mg tablets

Pack
60 tablet

Nicorandil 20mg tablets

Pack
60 tablet

Perhexiline

Unlicenced Drug { Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Consultant cardiologist recommendation only.

Unlicensed in UK.

Measure levels.

Perhexiline 100mg tablets

Pack
100 tablet

Ranolazine

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Ranolazine 375mg modified-release tablets

Pack
60 tablet

Ranolazine 500mg modified-release tablets

Pack
60 tablet

Ranolazine 750mg modified-release tablets

Pack
60 tablet

Tirofiban

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

To be used as adjunct to PTCA.

Tirofiban 12.5mg/50ml solution for infusion vials

Pack
1 vial

Tirofiban 12.5mg/250ml infusion bags

Pack
1 bag
  • 2.8.1 Acute coronary syndromes
  • 2.8.1a Cardiac arrest

Online Formulary by M.O.M. Systems

NICE guidance is available from https://www.nice.org.uk/guidance All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

© Copyright 2025